1. Home
  2. NUVL vs AGNC Comparison

NUVL vs AGNC Comparison

Compare NUVL & AGNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NUVL
  • AGNC
  • Stock Information
  • Founded
  • NUVL 2017
  • AGNC 2008
  • Country
  • NUVL United States
  • AGNC United States
  • Employees
  • NUVL N/A
  • AGNC N/A
  • Industry
  • NUVL Biotechnology: Pharmaceutical Preparations
  • AGNC Real Estate Investment Trusts
  • Sector
  • NUVL Health Care
  • AGNC Real Estate
  • Exchange
  • NUVL Nasdaq
  • AGNC Nasdaq
  • Market Cap
  • NUVL 6.7B
  • AGNC 7.9B
  • IPO Year
  • NUVL 2021
  • AGNC 2008
  • Fundamental
  • Price
  • NUVL $75.84
  • AGNC $9.61
  • Analyst Decision
  • NUVL Strong Buy
  • AGNC Buy
  • Analyst Count
  • NUVL 11
  • AGNC 10
  • Target Price
  • NUVL $112.36
  • AGNC $10.43
  • AVG Volume (30 Days)
  • NUVL 558.9K
  • AGNC 19.1M
  • Earning Date
  • NUVL 02-25-2025
  • AGNC 01-27-2025
  • Dividend Yield
  • NUVL N/A
  • AGNC 14.98%
  • EPS Growth
  • NUVL N/A
  • AGNC 352.69
  • EPS
  • NUVL N/A
  • AGNC 1.40
  • Revenue
  • NUVL N/A
  • AGNC $1,259,000,000.00
  • Revenue This Year
  • NUVL N/A
  • AGNC N/A
  • Revenue Next Year
  • NUVL N/A
  • AGNC $1,501.03
  • P/E Ratio
  • NUVL N/A
  • AGNC $6.87
  • Revenue Growth
  • NUVL N/A
  • AGNC 226.17
  • 52 Week Low
  • NUVL $61.80
  • AGNC $8.92
  • 52 Week High
  • NUVL $113.51
  • AGNC $10.85
  • Technical
  • Relative Strength Index (RSI)
  • NUVL 38.09
  • AGNC 58.57
  • Support Level
  • NUVL $69.58
  • AGNC $8.96
  • Resistance Level
  • NUVL $78.18
  • AGNC $9.48
  • Average True Range (ATR)
  • NUVL 3.03
  • AGNC 0.15
  • MACD
  • NUVL 0.04
  • AGNC 0.04
  • Stochastic Oscillator
  • NUVL 50.40
  • AGNC 94.20

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About AGNC AGNC Investment Corp.

AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage or real estate markets.

Share on Social Networks: